Li Zijian
Professor/Researcher, PhD Supervisor
Research Interests: Cardiovascular receptors and cardiovascular diseases, Clinical pharmacy in cardiovascular medicine
Tel: +86-010-87132335
Email: lzjgy1995@163.com
EDUCATION
Doctor of Philosophy, Jilin University (2003)
Master of Science, Jilin University (1999)
PROFESSIONAL EXPERIENCE
2014 - present Peking University Third Hospital, Institute of Vascular Medicine
Professor/Researcher (2014)，Associate Professor (2007), Assistant Researcher (2005)
2008.1－2010.1 Department of Pharmacy, Emory University, USA
Postdoctor
2003.9－2005.9 Peking University , Institute of Cardiovascular Medicine, Institute of Vascular Medicine, Third Hospital, Key Laboratory of Cardiovascular Medicine of the Ministry of Education
Postdoctor
ACADEMIC APPOINTMENTS
Director of the Beijing Key Laboratory of Cardiovascular Receptors Research (2022)
Secretary-general of the Chinese Society of Pathophysiology（2025）
Chairperson of the Vascular Medicine Professional Committee of the Chinese Society of Pathophysiology (2025)
Vice Chairman of the 12th Council of the Chinese Society of Pathophysiology (2025)
Standing Director of the 12th Council of the Chinese Society of Pathophysiology (2025)
Chairperson of the Cardiovascular and Cerebrovascular Pharmacology Professional Committee of the Beijing Pharmacological Association (2024)
Member of the Fourth Council of Beijing Pharmacological Society (2023)
Standing Committee Member of the Medical Genomics and Bioinformatics Professional Committee of the China Medical Education Association (2022)
Member of the Fourth Council of the Chinese Society of Micro and Nano Technology (2021)
Member of the 13th Standing Committee of the Cardiovascular Pharmacology Professional Committee of Chinese Pharmacology (2021)
Member of the Clinical Research and Translational Professional Committee of Beijing Pharmaceutical Association (2021)
Member of the Metabolic Cardiovascular Disease Group, Cardiovascular Disease Branch, Chinese Medical Association (2019)
Standing Committee Member of the 12th Committee of the Cardiovascular Pharmacology Professional Committee of Chinese Pharmacology (2018)
AWARDS AND CERTIFICATES
Second Prize of Huaxia Medical Science and Technology Award (2025)
Third Prize of the Chinese Medical Science and Technology Award of the Chinese Medical Association (2025)
The Special Award (Promotion Award) of the 8th Chinese Society of Management Science Management Award (2022)
Chinese Hospital Association Hospital Science and Technology Innovation Award (2021)
Third Prize of Science and Technology of the Chinese Pharmaceutical Association (2020)
First Prize of Shaanxi Science and Technology Award (2020)
First Prize of Shaanxi Science and Technology Award (2015)
REPRESENTATIVE PUBLICATIONS(2022-2025)
1. Yunqi Jiang, Dannya Estau, Yuhui Qiao, Zijian Li*. 14-3-3/HIP-55 complex attenuates cardiomyocyte apoptosis. J Mol Cell Cardiol. 2025 Sep;206:91-101.（IF: 4.7/Q1）
2. Xueqing Tang, Dannya Estau, Xiaoru Huang, Zijian Li*. Edaravone targets PDGFRβ to attenuate VSMC phenotypic transition. Life Sci. 2025 Mar 18;370:123568.（IF: 5.3/Q1）
3. Kaihang Guan, Zijian Li*.β-adrenergic receptor inhibits heart regeneration by downregulating Yap m6A modification. Cell Death Dis. 2025;16(1):294. (IF: 9.6/Q1)
4. Xuening Liu, Zijian Li*. The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity. Basic Res Cardiol. 2025;120(1):11-24.（IF: 8.0/Q1）
5. Xiaoru Huang, Xuening Liu, Zijian Li*. Bile acids and coronavirus disease 2019. Acta Pharm Sin B. 2024 May;14(5):1939-1950.（IF: 14.7/Q1）
6. Yunqi Jiang, Jinge Gu, Xiaodou Niu, Jiaojiao Hu, Yongzhen Zhang, Dan Li, Yida Tang, Cong Liu, Zijian Li*. Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.[J]. Circulation, 2024;150(12):938-951.（IF:37.8/Q1）
7. Jingwei Bian, Yuzong Zhu, Panhui Tian, Qiqi Yang, Zijian Li*. Adaptor protein HIP-55 promotes macrophage M1 polarization through promoting AP-1 complex activation. Cell Signal. 2024;117:111124. （IF:4.8/Q2）
8. Xiaoru Huang, Dannya Estau, Xuening Liu, Yang Yu, Panhui Tian, Zijian Li*, Effect of sodium‑glucose cotransporter‑2 inhibitors on myocardial infarction incidence: a systematic review and meta‑analysis of randomized controlled trials and cohort studies, Diabetes, Obesity and Metabolism.2024Mar;26(3):1040-1049. (IF: 5.8/Q1)
9. Huang Xiaoru, Estau Dannya, Liu Xuening, Yu Yang, Qin Jiguang, Li Zijian*. Evaluating the performance of ChatGPT in clinical pharmacy: A comparative study of ChatGPT and clinical pharmacists. British journal of clinical pharmacology, 2024;90(1):232-238.（IF: 3.4/Q2）
10. Kaihang Guan, Kai Liu, Yunqi Jiang, Jingwei Bian, Yang Gao, Erdan Dong, and Zijian Li*. Nanoparticles Internalization through HIP-55-Dependent Clathrin Endocytosis Pathway. Nano Letters 2023 23 (24), 11477-11484.（IF: 10.8/Q1）
11. Yunqi Jiang, Yuhui Qiao, Dan He, Aiju Tian, Zijian Li*. Adaptor protein HIP-55-mediated signalosome protects against ferroptosis in myocardial infarction. Cell Death Differ. 2023 Mar;30(3):825-838. (IF: 12.067/Q1)
12. Shiqi Chen , Panhui Tian, Dannya Estau, Zijian Li*. Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Front Cell Dev Biol. 2023 Jan 27;11:1076107. (IF: 6.081/Q2)
13. Wenqi Li, Yuzhong Zhu, Wenjing Wang, Dan He, Lei Feng*, Zijian Li*. Src tyrosine kinase promotes cardiac remodeling induced by chronic sympathetic activation. Biosci Rep. 2023 Oct 31;43(10):BSR20231097. (IF: 4/Q2)
14. Nana Zhang, Haibo Zhu*, Zijian Li*, Erdan Dong. A novel β2-AR agonist, Higenamine, induces β-arrestin-biased signaling. Sci China Life Sci. 2022 Jul;65(7):1357-1368.（IF: 10.372/Q1）
15. Nana Zhang, Fengzhong Wang, Zijian Li*, Haibo Zhu*. Higenamine as a Potential Pharmacologic Stress Agent in the Detection of Coronary Artery Disease. Chin Med Sci J. 2022 Sep 30;37(3):275-281.（IF: 5.4/Q1）
16. Xueqing Tang, Jingwei Bian, Zijian Li*. Posttranslational modifications in GPCR internalization. Am J Physiol Cell Physiol. 2022 Jul 1;323(1):C84-C94.（IF: 5.5/Q2）
17. Yang Sun and Zijian Li*. The multifunctional adaptor protein HIP-55 couples Smad7 to accelerate TGF-β type I receptor degradation. Acta Pharmacol Sin. 2022;43(3):634-644.（IF: 7.169/Q1）
18. Wenjing Wang, Jingwei Bian, Yang Sun, and Zijian Li*. The new fate of internalized membrane receptors: Internalized activation. Pharmacol Ther. 2022 May;233:108018. (IF: 13.5/Q1)